医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata NEXT Seoul and Shanghai Events Host Industry Thought Leaders at the Forefront of the Digital Transformation in Life Sciences

2018年07月12日 AM06:58
このエントリーをはてなブックマークに追加


 

SHANGHAI

This week, the Asia Pacific segment of Medidata’s (NASDAQ:MDSO) global NEXT series continues with customer events in Seoul and Shanghai. Sessions will explore trends in virtual trials, mobile healthcare, real-world evidence, artificial intelligence, and machine learning.

The digital transformation of clinical trials is among the many topics being discussed by company executives and hundreds of life science leaders in the region.

NEXT Seoul concluded Tuesday with more than 400 attendees. Keynote speakers included Professor Daeho Lee from Asan Medical Center who discussed the importance of patient centricity in clinical research, and Mr. Sangjoon Lee who outlined how technology revolutionized new drug development for his company, Celltrion.

NEXT Shanghai takes place Thursday, with over 800 attendees expected from leading pharmaceutical companies, including Fosun, and 13 CRO sponsors, including Paraxel, TigerMed, FMD K&L, and Wuxi CDS. Keynote speakers from China Drug Administration (formerly CFDA) and University of Tokyo Hospital in Shanghai will explore the future blueprint of drug development.

“This week is a great opportunity for life science leaders in the region to share insight about the future of drug development,” said Glen de Vries, president and co-founder, Medidata. “I’m excited to join over 1,200 customers and partners as we discuss the digital transformation of our industry.”

Learn more about Medidata NEXT global events and register today for NEXT NYC.

About Medidata

Medidata is leading the digital transformation of life sciences, with the world’s most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users everyday to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005864/en/

CONTACT

Medidata Solutions
Investors:
Betsy Frank, 917-522-4620
bfrank@mdsol.com
or
Media:
Erik
Snider, 646-362-2997
esnider@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 22ndセンチュリーはFDAのニコチン低減計画が直ちに実行可能であると発表
  • Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital
  • Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market
  • 22nd Century宣布可立即执行FDA的尼古丁削减规划
  • New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis